In January 2016, more than 2,500 of the world’s most influential business, political, and societal leaders attended the 46th World Economic Forum Annual Meeting in Davos, Switzerland where for four days they debated topics such as the global economy, the rise of robots, modern medicines, terrorism and cybercrime. Mallinckrodt Pharmaceuticals President and CEO, Mark Trudeau served as a featured speaker in the panel discussion titled, “Forum Debate: A Cure We Can Afford” that explored the major drivers of the drug pricing debate.
Trudeau spoke about the positive role the pharmaceutical industry plays in discovering and bringing life-saving medicines to patients across the world, as well as the importance of having adequate incentives for manufacturers to counter-balance the financial risk and time commitment these companies bear when developing new treatments.
He also addressed the growing public concerns over rising healthcare costs, calling for all stakeholders – governments, industry, healthcare professionals and patients – to work together toward developing sustainable solutions that provide value to the healthcare system, while minimizing costs. Trudeau emphasized the importance of new approaches to drug development that reduce costs and time to approvals, assuring efficient pathways for generic drugs, and initiatives that more closely tie payment for drugs to improvement in health outcomes.
“It was an honor to take part in the World Economic Forum,” said Mark. “Having the opportunity to collaborate and share insights with government, academic and private sector leaders was tremendously helpful to our business and our understanding of the changing environment in which we operate.”
Pictured above, from left: Simon Stevens, Chief Executive, National Health Service of the UK; Mark Trudeau, President and CEO, Mallinckrodt; Zeke Emanuel, Vice-Provost, Global Initiatives and Professor of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania.